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Variations in genetic mutations in pancreatic carcinoma between
different populations have not been studied extensively, especially
in developing countries where pancreatic cancer is rare. We stud-
ied the molecular pathology of 44 pancreatic carcinomas from
patients residing in a heavily polluted region in the Nile River
delta and compared the findings with tumors from 44 United
States (US) patients. We evaluated K-ras mutations in codon 12,
p53 mutations in exons 5–8, and Gadd45a mutations in exons 1
and 4. Overall, rates of K-ras, p53 and Gadd45 mutations were not
statistically different in tumors of patients from Egypt and the US
(67.4 vs. 63.4%; 27.3 vs. 36.4% and 9.1 vs. 4.5%, respectively).
However, there were distinct differences in the specific types of
K-ras and p53 mutations between the 2 groups. In K-ras, G fi T
transversion mutation was more frequent in the tumors from
Egypt than from the US (58.6 vs. 26.9%), whereas G fi C trans-
version was detected in 26.9% of US tumors but none from Egypt
(p 5 0.003). We also found a trend toward differences in the p53
exons in which mutations occurred, with higher frequency of exon
5 mutation and lower frequency of exon 6 mutation in Egyptian
tumors. Logistic regression showed that K-ras G fi T transversion
mutations and p53 exon 6 mutations were predicted by the coun-
try of residence of the patients. Our study identifies that there are
differences in the types of mutations found in tumors from pancre-
atic carcinoma patients in Egypt and the US, and suggests that
environmental factors may explain these differences.
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Studies of unusual cancer distribution and analysis of particular
genetic mutations may provide clues to cancer etiology. We previ-
ously reported high incidence and mortality rates for colorectal
carcinoma in young patients under age 40 in Egypt as compared to
the United States.1,2 We also reported patterns of genetic mutations
in Egyptian colorectal cancers that were distinct from Western
patients.3 During our research on the epidemiology of colorectal
cancer in Egypt, we observed an area in the northeast Nile River
delta region with a high incidence of pancreatic cancer.4 This region
is known to have the highest environmental pollution of pesticides
and heavy metals in Egypt.5–9
Pancreatic cancer incidence rates vary considerably throughout
the world, with the highest rates occurring in developed coun-
tries.10,11 This cancer shows a wide range of geographic incidence
variation in the US with the Louisiana wetlands area and the
Mississippi River delta regions reporting the highest rates.12
Pancreatic cancer has not been widely reported in developing
countries, except for the one area of high incidence we identified
in the northeast Nile River delta region of Egypt.4,13
The molecular genetics of pancreatic carcinoma have been stud-
ied in detail. Mutations in the K-ras proto-oncogene and p53 gene
are common, and Gadd45 mutations have been identified.14 The
study reported here was designed to evaluate the rates and types of
these mutations in tumors from Egyptian patients who reside in
the geographical region of extensive environmental pollution. The
study also compared and contrasted the mutation characteristics
with those of patients in the US.
Material and methods
This study included tumors obtained from surgically resected
Stage II and III pancreatic cancer15 patients in Egypt at the Gastro-
intestinal Surgery Center (GSC) of Mansoura University and in
the US at the University of Texas, M. D. Anderson Cancer Center
in Houston. The group from Egypt included 44 newly diagnosed
patients with histopathologically confirmed ductal adenocarci-
noma of the pancreas. The Egyptian cases represent all consecu-
tive patients undergoing resection of the pancreas who had prelim-
inary histopathological diagnosis of pancreatic adenocarcinoma
and confirmation of the diagnosis in Houston by one of the authors
(SRH). All Egyptian patients were residents of the Dakahleia
Province where the GSC is located, and no age or gender restric-
tions were applied. The 44 Egyptian patients were all the patients
who had surgical resections during the period of the study with re-
cruitment from November 1998 to February 2000. These patients
represented 26% of all incident pancreatic cancer patients seen at
the study hospital during this period. This rate of histopatholgical
confirmation in a developing country is lower than rates of histo-
pathological confirmation in developed countries.16
The second group of tumors was obtained as archival tissue
from the surgical pathology files of 44 selected US patients who
underwent diagnosis and treatment for adenocarcinoma with sur-
gical resection of the pancreas between 1992 and 2004 at The Uni-
versity of Texas, M. D. Anderson Cancer Center in Houston.
Because of the young age of onset in Egyptian patients, the US
cases were matched to the Egyptian patients as closely as possible
by age (610 years) and gender. Matching was successful for 40
pairs of patients, and 4 US patients were matched for age, but not
Grant sponsor: Eli Lilly Research; Grant sponsor: Topfer Research fund
from M. D. Anderson; Grant sponsor: National Cancer Institute; Grant
numbers: CA K07 090241, R03 CA099513-01; Grant sponsor: University
of Michigan’s Cancer Center; Grant number: 5 P30 CA46592.
*Correspondence to: Department of Epidemiology, School of Public
Health, University of Michigan, 109 Observatory Road, Ann Arbor, MI
48109, USA. Fax:1734-764-3192. E-mail: asoliman@umich.edu
Received 20 September 2005; Accepted after revision 22 February 2006
DOI 10.1002/ijc.21986
Published online 17 April 2006 inWiley InterScience (www.interscience.
wiley.com).
Int. J. Cancer: 119, 1455–1461 (2006)
' 2006 Wiley-Liss, Inc.
Publication of the International Union Against Cancer
for gender. Pancreatic cancer patients at M. D. Anderson Cancer
Center represent the following 3 groups: (i) Patients diagnosed
clinically and/or pathologically at the center (39% of patients),
who therefore have pathologic specimens available for study; (ii)
Patients diagnosed outside the center, who have subsequent clini-
cal and/or pathological diagnosis confirmed at M. D. Anderson
Cancer Center (52%) and therefore have pathologic specimens
available; (iii) Patients diagnosed outside the center without tissue
confirmation (9%). The 44 US patients were among the first 2
described groups. A list of all patients who fulfilled the age-match-
ing criteria (i.e.,610 years) and gender was created.
The case–case design we used allows the comparison between
case groups or across case subtypes. This design was first pro-
posed by Begg and Zhang (1994)17 to provide more efficient esti-
mation of etiologic contrast parameters. It also allows the identifi-
cation of factors that are differentially related to disease subtypes
or different groups of cases from more than one population. Case–
case odds ratio estimates highlight the relative strength of covari-
ate-outcome associations between the 2 case groups.18 Limitations
of case–case analysis include lack of estimation of relative risk
because of lack of control subjects. Case–case design has been
used to explore differences in genetic mutational rates and types
in different studies including ours.3,19–21
Ductal adenocarcinoma of the pancreas was confirmed by histo-
pathological review (SRH). The Egyptian patients included in this
study were participants in an ongoing case–control study to inves-
tigate the association between pancreatic cancer and cadmium ex-
posure in Dakahleia, Egypt. Interviewers elicited epidemiologic
information using a questionnaire that was used and tested in pre-
vious studies.1,22,23 The questionnaire allowed collection of infor-
mation about demographics, occupation (agricultural, professional
and technical or administrative), residence (urban vs. rural), smok-
ing and any family history of cancer. Interviews took place during
hospital admission of patients for their preoperative investigations.
Patients in Egypt are routinely admitted to hospitals for a period
of 3–7 days before surgery for such preoperative clinical and labo-
ratory evaluations. Trained interviewers who participated in our
previous studies3,23,24 conducted the interviews.
The medical records of the patients from M. D. Anderson Can-
cer Center were reviewed to retrieve the same data elements. A
trained study coordinator at M. D. Anderson Cancer Center con-
ducted the abstraction of medical records. The coordinator was
supervised by 2 of the coauthors (ASS and MLB).
Because place of residence reported in the records of M. D.
Anderson denoted only residence at the time of surgery, we could
not determine the place of longest residence for these patients, and
we did not use this variable in the data analysis of US patients.
The study was approved by IRB committees in Egypt and the US.
Laboratory methods
Microdissection and DNA extraction. Areas of adenocarci-
noma and non-neoplastic control tissue were microdissected from
routine formalin-fixed, paraffin-embedded tissue sections cut
5-lm thick and stained with hematoxylin and eosin. DNA was
extracted as in our previous studies.25,26 Approximately one
square centimeter of tumor tissue was wet with xylene, scraped
from the slide using a clean razor blade and placed into a micro-
centrifuge tube. The xylene was removed by vacuum centrifuga-
tion until completely dry. Each specimen was then treated with
50 ll of buffer containing 0.5% Tween 20 (Boehringer Mannheim,
Mannheim, Germany), 20 lg Proteinase K (Boehringer Mann-
heim, Mannheim, Germany), 50 mM Trizma Base at pH 8.9 and
2 mM EDTA. The samples were incubated at 56C overnight. Pro-
teinase K was inactivated by incubating the samples at 100C for
10 min. A 1:20 dilution of the DNA lysate in nuclease-free water
was used for PCR amplification. The extracted DNA was stored at
220C until analysis.
K-ras PCR amplification. We evaluated codons 12 and 13 of
the K-ras gene.27 The mutations were classified for location in
either the first or the second base. The 2 bases of K-ras were
amplified in a 50 ll reaction volume using 2 ll of genomic DNA,
13 PCR Buffer II, 2 mM magnesium chloride, 0.8 mM dNTP
mix, 2.25 U Ampli TaqTM Gold (Applied Biosystems, CA), 0.125
U Pfu DNA Polymerase (Stratagene, CA) and 20 pmol of each
primer (forward primer, 50-GGCCGGTAGTGTATTAACCTTATG-
TGTGACAT-30, and reverse primer, 50CCGCGGCCGGCGGCC-
AAAACAAGATTTACCTCTATTGTTGG-30, Life Technologies,
MD). PCR reactions were carried out using the following touch-
down cycling conditions: denaturation at 95C for 10 min; 14 cycles
(95C 3 20 sec, 59C 3 60 sec [20.5C/cycle] and 72C 3
60 sec), 25 cycles (95C 3 20 sec, 52C 3 60 sec and 72C 3
60 sec); and extension at 72C for 10 min. Thermal cycling was per-
formed using a GeneAmp PCR System 9700 (Applied Biosystems,
CA). The quality of the product was analyzed on a 6% polyacryl-
amide gel.
p53 PCR amplification. Exons 5 through 8 of the p53 gene
were amplified separately in 50 ll volumes using 2 ll of the
1:20 diluted DNA lysate, 13 PCR Buffer II (Applied Biosystems,
CA), an additional 100 nmol magnesium chloride, 40 nmol dNTP
mix, 1.25 U Ampli TaqTM Gold (Applied Biosystems, CA) and
20 pmol of sense and antisense primer. The primer sequences were
as follows:
Exon 5 (sense) 50-GACTTTCAACTCTGTCTCC-30, Exon 5
(antisense) 50-GAGCAATCAGTGAGGAATC-30, Exon 6 (sense)
50-TCCCCAGGCCTCTGATTCC-30, Exon 6 (antisense) 50-TGA-
CAACCACCCTTAACCC-30, Exon 7 (sense) 50-CAAGGCGCAC-
TGGCCTCATC-30, Exon 7 (antisense) 50-CACAGCAGGCCAG-
TGTGCAG-30, Exon 8 (sense) 50-GATTTCCTTACTGCCTCTTGC-
30 and Exon 8 (antisense) 50-GTGAATCTGAGGCATAACTGC-30.
PCR amplification was carried out using the following cycling
conditions: Exons 6 and 8, denaturation at 95C for 10 min, 45
cycles (95C3 60 sec, 61C3 60 sec, 72C3 60 sec), and exten-
sion at 72C for 5 min; Exon 7, denaturation at 95C for 10 min,
45 cycles (95C 3 60 sec, 65C 3 60 sec, 72C 3 60 sec), and
extension at 72C for 5 min; Exon 5 denaturation at 95C for
10 min, 45 cycles (95C 3 60 sec, 55C 3 60 sec, 72C 3
60 sec), and extension at 72C for 5 min. Thermal cycling was
performed using a GeneAmp1 PCR System 9700 (Applied Bio-
systems, CA). The quality of the product was examined and quan-
titated on a 2.0% agarose gel.
Gadd45 PCR amplification. The GADD45a gene fragment was
amplified by PCR. Exon 1 and exon 4 were 265 and 397 bp,
respectively. The PCR primers used were 50-GCCTGTGAGT-
GAGTGCAGAA-30 (sense) and 50-GGAGTT GCCCTGTGCAAA-
CT-30 (antisense) for exon 1 and 50-GAACCCAACTACCTTGAA-
GA-30 (sense) and 50-CCCCTTGGCATCAGTTTCTG-30 (antisense)
for exon 4. The sequencing primers were 50-TAGCCGTGGCAG-
GAGCAG-30 (sense) for exon 1 and 50-TGTCTCCATGTCACA-
TAGCC-30 (sense) for exon 4. The PCR was run in 35 cycles con-
sisting of denaturation at 94C for 1 min, annealing at 55C for
45 sec and extension at 72C for 2 min with a Thermal cycler (Perkin-
Elmer, Norwalk, CT).
Automated DNA Sequencing for K-ras and p53 mutations. PCR
products were diluted to 5 ng/ll and purified by mixing 5 ll of
PCR product dilution with 2 ll Exo/SAP (Amersham Life Sci-
ence, OH), incubated at 37C for 15 min, and then inactivated by
incubating at 80C for 15 min. DNA sequencing was performed in
20 ll volumes using 2 ll purified PCR product, 4 ll ABI PRISM1
BigDyeTM Terminator Cycle Sequencing Kit (Applied Biosys-
tems, CA), and 10 pmol of forward primer using the following cy-
cling conditions: initial denaturation at 95C 3 5 min followed by
25 cycles of 95C 3 20 sec, 52C 3 60 sec and 60C 3 60 sec.
Following spin-column purification (Princeton Separations, NJ)
and resuspension in 10 ll formamide, the reaction products were
sequenced by capillary electrophoresis using an ABI PRISMTM
3700 or ABI 3730 DNA Analyzer (Applied Biosystems, CA). The
sequences of samples containing mutations were confirmed using
the reverse primer.
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Gadd45 sequence analysis. We used the ABI Prism 310
Genetic Analyzer (Perkin-Elmer Corp., Foster City, CA) for direct
DNA sequencing. The PCR products were electrophoresed on a
2% agarose gel containing 0.5 mg/ml of ethidium bromide. The
band of interest was excised and purified with a QIAquick Gel
Extraction Kit (QIAGEN GmbH, Hilden, Germany). A Microcon-
100-Column (Millipore, Bedford, MA) was used to purify the
PCR products without ectopic sites and confirmed by electropho-
resis. For automated cycle sequencing, 20–40 ng of purified PCR
product was subjected to sequencing PCR in a total volume of
20 ll of PCR reaction mixture containing 3.2 pmol of p53 sequenc-
ing primer (sense) and 8 ll of BigDye Terminator Ready Reaction
Mix (Applied Biosystems). The sequencing reaction was carried out
in a DNA Thermal Cycler 480 (Perkin-Elmer) for 20 cycles for exons
1 and 4. Each cycle consisted of denaturation at 96C for 30 sec,
annealing at 50C for 15 sec and extension at 60C for 4 min. Etha-
nol precipitation was used to purify the sequencing PCR products.
After being denaturated at 95C for 3 min, the purified sample was
electrophoresed on an ABI Prism 310 Genetic Analyzer (PE Applied
Biosystems, Foster City, CA). Sequencing Analysis and Sequence
Navigator Software (Applied Biosystems) were used to analyze the
sequence data.
Statistical methods and analysis. Differences in frequencies
between the Egyptian and US groups were evaluated by simple
contingency table analysis (Fisher’s exact probability test) using
the SAS1 statistical package (SAS1v8.2). Variables that were
included in this analysis were age (used as a continuous variable),
gender (male vs. female), smoking (yes vs. no), and residence for
Egyptians (rural versus urban). Residence data for Egyptian
patients reflected lifetime residence, which was not available for
the US patients. Occupation was classified into 3 groups (agricul-
tural, professional and technical or administrative), and family
history of pancreatic cancer and family history of cancer in any
relative were scored as yes vs. no. Total frequencies of K-ras, p53
and Gadd45 mutations were used in the analysis as categorical
variables, using single nucleotide changes and position.
Unconditional logistic regression models were computed to test
associations between mutations or mutation types and demographic,
occupational and lifestyle factors. Contingency tables were con-
structed yielding chi-squared p-values, Fisher’s exact p-values,
crude odds ratio (OR) and 95% confidence interval (95% CI). Sepa-
rate multiple logistic regression models were constructed for statisti-
cal analysis of K-ras G fi T mutation and p53 mutation in exon 6
as the dependent variables with other variables (e.g., residence, gen-
der, smoking and farming related occupations) as the covariates to
test for confounding and effect modification.
Results
Patient characteristics
The Egyptian patients were young (mean age of 52.76 10.3 years)
relative to the usual age of patients with pancreatic cancer in the US.
Matching of cases for age was successful, as the mean age of the
selected US patients was 53.7 6 10.4 years (p 5 0.665) (Table I).
Males constituted 56.8 and 65.9% of the study sample from Egypt
and the US, respectively, while females constituted 43.2 and
34.1%, respectively (p 5 0.381) (Table I). There was no statisti-
cally significant difference between Egyptian and US patients re-
garding smoking (p 5 0.134) (Table I). However, more Egyptian
patients held farming related occupations (27.3%) than US
patients (6.8%). Family history of cancer in any relative, and his-
tory of pancreatic cancers in relatives were significantly more fre-
quent among US patients than among Egyptian patients: 50.0 and
4.5% for family history of cancer in US and Egyptian patients,
respectively, and 9.1 and 0% for family history of pancreatic can-
cer in US and Egyptian patients, respectively (Table I).
Mutation frequencies
K-ras amplification and sequencing was successful in 43/44
(97.7%) of tumors from the US and in 41/44 (93.2%) of tumors
from Egypt (p 5 0.3061). p53 amplification and sequencing was
successful in all tumors. Gadd45 amplification and analysis was
successful in 37/44 (87.1%) of tumors from Egypt and 27/44
(61.4%) of tumors from the US (p5 0.0167) (Table I).
Overall, the rates of K-ras, p53 and Gadd45 mutations were not
statistically different in tumors of patients from Egypt and the US
(65.9 vs. 59.1%, 27.3 vs. 36.4%, and 9.1 vs. 4.5%, respectively)
(Table II). Over one-quarter (27.6%) of Egyptian patients and
28.6% of US patients had both K-ras and p53 mutations (p 5 0.946)
(Table II).
Tumors from 2 Egyptian patients, but none of the tumors from
the US, had concurrent mutations in all 3 genes (K-ras, p53 and
TABLE I – CHARACTERISTICS OF PANCREATIC ADENOCARCINOMA







Mean 6 SD 52.70 6 10.27 53.666 10.35 0.665
Gender
Male 25 (56.8) 29 (65.9)
Female 19 (43.2) 15 (34.1) 0.381
Smoking**
Yes 25 (56.8) 29 (72.5) 0.134
No 19 (43.2) 11 (27.5)
Residence
Rural 26 (59.1) N/A N/A
Urban 18 (40.9) N/A
Occupation
Farming-related 12 (27.3) 3 (6.8) 0.011
Non-farming 32 (72.7) 41 (93.2)
Family history of pancreatic cancer
Yes 0 (0) 4 (9.1) 0.042
No 44 (100) 40 (90.9)
Family history of any cancer
Yes 2 (4.5) 22 (50.0) <0.0001
No 42 (95.5) 22 (50.0)
Genetic characteristics
K-ras codon 12
Mutation 29 (65.9) 26 (59.1) 0.698
Wild Type 14 (31.8) 15 (34.1)
Unavailable 1 (2.3) 3 (6.8)
p53 exons 5–8
Mutation 12 (27.3) 16 (36.4) 0.360
Wild type 32 (72.7) 28 (63.6)
Unavailable 0 0
Gadd45 exons 1 and 4
Mutation 4 (9.1) 2 (4.5) 0.693*
Wild Type 32 (72.7) 25 (56.8)
Unavailable 7 (16) 17 (38.6) 0.017




Values in parentheses indicate percentage values.
*p of Fisher’s exact test.
**Data unavailable for 4 US patients.
TABLE II – DISTRIBUTION OF K-RAS, P53, AND GADD45 MUTATION
POSITION IN PANCREATIC ADENOCARCINOMAS OF PATIENTS FROM





K-ras Codon 12a 2 (6.9) 6 (23.08) 0.007
Codon 12b 27 (93.1) 20 (76.9)
p53 5 6 (21.4) 3 (10.7) 0.134*
6 2 (16.7) 9 (56.3)
7 2 (16.7) 1 (6.3)
8 2 (16.7) 3 (18.8)
Gadd45 1 0 (0) 0 (0) N/A
4 4 (100.0) 2 (100.0)
Values in parentheses indicate percentage values.
*Fisher’s exact test.
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Gadd45). In tumors from US patients with a family history of pan-
creatic cancer, 1 patient had a K-ras 12b G fi A mutation, and
another had a 12b G fi T mutation. One patient had both a p53
(exon 6 T fi G) and K-ras mutation (12b Gfi T).
Types of mutations
The rates of individual mutations of K-ras and p53 were differ-
ent between the 2 groups of tumors. K-ras mutations showed a
higher rate of mutation in codon 12a in tumors from the US than
in tumors from Egypt (23.1 vs. 6.9%, p 5 0.007) (Table II). We
also found that the 2 groups of tumors had specific K-ras mutations
with different frequencies (Fisher’s exact p 5 0.003) (Table III).
The frequency of G fi A transitions was similar between Egyptian
and US tumors at 41.4 and 46.2%, respectively, with the most note-
worthy difference observed in G fi T and G fi C transversions.
K-ras G fi T transversions appeared in 58.6% of the Egyptian
tumors and in 26.9% of the US tumors. The K-ras G fi C transver-
sions appeared in none of the Egyptian tumors and in 26.9% of the
US tumors (Table III).
There was also a trend toward different individual types of p53
mutations, although the differences were not statistically signifi-
cant. About one-fifth (21.4%) of p53 mutations in Egyptian tumors
were in exon 5 vs. 10.7% of tumors from the US. On the contrary,
p53 exon 6 mutations were more frequent in tumors from the US
56.3 vs. 16.7% in tumors from Egypt. Among tumors with p53
mutations, exon 7 mutations were somewhat more frequent in
tumors from Egypt than in tumors from the US (16.7 vs. 6.3%).
Exon 8 mutations in tumors from Egypt and the US were present
in 16.7 vs.18.8%, in Egypt and the U.S., respectively (Table II).
Although comparison of all types of p53 mutations in tumors from
Egypt and the US was not statistically significant (p 5 0.134)
(Table II), pancreatic cancers from the US were more likely to
have mutations in p53 exon 6 when compared to the frequency of
mutations in exons 5, 7 and 8 combined (p 5 0.044) (Table V).
Gadd45 mutations were detected only in exon 4, and 9% of tumors
from Egypt had Gadd45 mutations compared with 4.5% of tumors
from the US (Table II).
We found that the 2 groups of tumors had specific K-ras muta-
tions with different frequencies (Fisher’s exact p 5 0.003) (Table III).
The frequency of Gfi A transitions was similar between Egyptian
and US tumors at 41.4 and 46.2%, respectively, with the most
noteworthy difference observed in Gfi T and Gfi C transversions.
K-ras G fi T transversions appeared in 58.6% of the Egyptian
tumors and in 26.9% of the US tumors. The K-ras G fi C trans-
versions appeared in none of the Egyptian tumors and in 26.9% of
the US tumors (Table III).
Association of mutations and patient characteristics
All tumors from the US with K-ras G fi T transversions were
from smokers (100%) (1 missing smoking data), while 41.2% of
tumors from Egyptian patients with this mutation were smokers
(p 5 0.017). Half the Egyptian tumors with K-ras G fi A transi-
tions were from farmers, while none of the US tumors with this
mutation were from farmers (Fishers exact p 5 0.014) (Table III).
No statistically significant differences were observed in occupa-
tion or smoking of patients whose tumors had G fi T transver-
sions from Egypt and the US. Additionally, we found that among
the Egyptian patients there was no association with having a K-ras
Gfi T transversion or a mutation in p53 exon 6 and living in a rural
vs. urban area (p 5 0.495 and p 50.9500, respectively) (data not
shown).
Logistic regression analysis showed that country of residence of
patients (Egypt vs. US) was an important predictor of K-ras G fi T
mutations (p5 0.020) (Table IV).
After adjusting for gender, smoking and occupation as potential
confounders, country of residence was strongly and independently
predictive of K-ras G fi T transversion (p 5 0.049), and no evi-
dence of confounding was identified when tested against other con-
founders (Table IV). We found that tumors from Egypt were 3.85
times more likely to have this mutation than others (95% CI: 1.23–
12.01).
Country of residence of patients was also an important predictor
of p53 exon 6 mutations in models that adjusted for gender, smok-
ing and occupation (Table V). Odds ratios of country of residence
ranged from OR 5 6.4 (CI: 0.8–204.9) (p 5 0.044) for the unad-
justed model to OR 5 24.2 (CI: 1.5–393.4) (p 5 0.025) for the
partially adjusted model that included gender and occupation. The
TABLE III – RELATIONSHIP BETWEEN SPECIFIC K-ras MUTATIONS AND
PATIENT CHARACTERISTICS





G fi T 17 (58.6) 7 (26.9) 0.0031
G fi A 12 (41.4) 12 (46.2)
G fi C 0 (0) 7 (26.9)
G fi T (17,7)**
Age
Mean 6 SD 53.29 6 10.71 53.71 6 10.96 0.933
Gender
Male 8 (47.1) 4 (57.1) 0.500*
Female 9 (52.9) 3 (42.9)
Smoking
Yes 7 (41.2) 6 (100.0) 0.017*
No 10 (58.8) 0 (0)
Residence
Rural 12 (70.6) 0 (0) N/A
Urban 5 (29.4) 0 (0)
Occupation
Farmers 4 (23.5) 1 (14.3) 1.00
Nonfarmers 13 (76.5) 6 (85.7)
G fi A (12,12)**
Age (years)
Mean 6 SD 52.83 6 10.77 58.25 6 8.01 0.176
Gender
Male 10 (83.3) 8 (66.7) 0.923*
Female 2 (16.7) 4 (33.3)
Smoking
Yes 11 (91.7) 9 (75.00) 0.953*
No 1 (8.3) 3 (25.00)
Residence
Rural 7 (58.3) 0 (0) N/A
Urban 5 (41.7) 0 (0)
Occupation
Farmers 6 (50.0) 0 (0) 0.014
Non Farmers 6 (50.0) 12 (100)
Values in parentheses indicate percentage values.
1Two-sided p from Fisher’s exact test.
*Right-sided p from Fisher’s exact test.
**Values in parentheses indicate number of tumors from Egypt and
US, respectively.
TABLE IV – LOGISTIC REGRESSION MODEL TO PREDICT G fi T
TRANSVERSIONS IN K-ras IN PANCREATIC ADENOCARCINOMAS
FROM EGYPT AND THE UNITED STATES
OR (95% CI) p-value*
Unadjusted Country
United States 1
Egypt 3.85 (1.23–12.01) 0.020
Adjusted Country
United States 1
Egypt 4.78 (1.22–18.67) 0.049
Sex
Male 2.43 (0.69–8.59) 0.169
Female 1
Smoking
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fully adjusted model that included gender, smoking and occupa-
tion showed an OR 5 12.9 (CI: 0.8–204.9) (p 5 0.068). The
model that included gender and smoking only showed OR 5 8.7
(CI: 0.8–99.1) (p 5 0.081). We observed that smoking did not add
significantly to the model and that the final model should be model
2 (Table V). However, we think that the 3-fold change in point
estimate between models 2 and 3 along with a 2-fold change in
the point estimate between models 1 and 2 reflect the impact of
geographical differences between mutation pattern and other cova-
riates in addition to country of residence.
Discussion
Although the rates of mutations in the K-ras, p53 and Gadd45
genes in the 2 groups of pancreatic adenocarcinomas included in
this study did not show a statistically significant difference, the
individual types of mutations showed distinct differences between
patients from Egypt and the US. The overall rates of K-ras, p53
and Gadd45 mutations observed in this study for tumors from
Egypt and the US were comparable to other previous studies.28–33
The prevalence of K-ras mutations in pancreatic cancer has
been reported in many studies with a wide range of frequencies. A
recent meta-analysis of the studies reporting on K-ras and pancre-
atic intraepithelial neoplasia (PanIN) published in peer-reviewed
journals from 1988 to 2003 showed a stepwise increase in K-ras
mutations with the grade of dysplasia of the PanIN lesions. K-ras
mutations were found in 36, 44 and 87% of PanIN-1a, 1b and 2–3
lesions, respectively (trend statistic p < 0.001).34 Previous studies
comparing the prevalence of K-ras mutations in tumors from Afri-
can-American and Caucasian pancreatic cancer patients in Detroit
showed K-ras mutations in 70% of African Americans and 73% of
Caucasians.35 Other studies showed K-ras mutations in 62, 71 and
75% in subjects from Japan,36 China37 and Austria,28 respectively.
p53 has been reported with rates between 50 and 75% in differ-
ent studies.38 Rates similar to ours have been reported in other
studies, i.e., 3836 and 41%.32
Only 4 tumors (11.1%) from Egyptian patients and 2 tumors
(6.5%) from US patients had Gadd45 mutations, all in exon 4.
Gadd45 mutations are uncommon in pancreatic cancer, and the
rate observed in this study in Egyptian tumors was similar to that
found in a previous study in Japan.14 However, the rate of Gadd45
mutations observed in tumors from US patients in this study was
lower than that reported in the study from Japan.14 Interpopulation
genetic differences resulting from selection of young US patients
for matching may be a reason for the differences in mutational
rates from previous studies.
The rates of specific mutations in K-ras and p53 in the tumors
from the 2 countries showed distinct differences in our study.
K-ras Gfi T mutations were significantly more frequent in tumors
from Egyptian patients than in US patients, and G fi C mutations
were identified in tumors from US patients, but not in any tumor
from Egyptian patients. Furthermore, exon 5 mutations in p53
were more frequent in tumors from Egyptian patients, while exon
6 mutations were more frequent in tumors from US patients. Rates
of types of K-ras and p53 mutations in tumors from US patients in
this study were comparable to previous studies from western coun-
tries.39 The distinct mutational types in this study (K-ras G fi T
mutations and p53 exon 6 mutations) were predicted by the coun-
try of patient’s residence (Egypt or the US), after adjusting for
age, gender, smoking and occupation.
Our study also found that a high proportion of Egyptian patients
were farmers and rural residents, with presumed exposure to orga-
nochlorine pesticides.1,22 Those compounds have been associated
with K-ras G fi T mutations in pancreatic cancer mutations in a
previous study in Spain.40 Other prevalent environmental expo-
sures in our Egyptian study locale include heavy metals, such as
cadmium and chromium.5–9 Our recent study in this region in
Egypt revealed significantly higher serum cadmium levels in pan-
creatic cancer patients than in controls.24 Using industrial assess-
ment, and the Finnish job-exposure matrix, Alguacil et al.20 ana-
lyzed the occupational exposures of 107 incident pancreatic cancer
patients from Spain. This study reported that the association
between chromium and K-ras mutations was statistically significant
for G fi T transversions. Hence, organochlorine pesticides and
heavy metals may have contributed to the types of mutations seen
in tumors from Egyptian patients at significantly higher rates than
tumors from the US.
About one-quarter (24.2%) of tumors from Egyptian patients
and 36.7% of tumors from US patients included in this study had
both K-ras and p53 mutations, which was similar to previous stud-
ies.32,41,42 Blanck et al.42 reported 64% of pancreatic cancer
patients with both K-ras and p53 mutations had the same type of
mutation (transition or transversion), which suggested an environ-
mental agent might have acted on both genes in a similar manner,
or that the particular DNA base is prone to mutation.42
Subjects included in this study had high rates of cigarette smok-
ing with higher rates in the US patients than in Egyptians. Smok-
ing has been linked to pancreatic cancer in many studies and has
been the most consistent risk factor for pancreatic cancer. How-
ever, smoking was not related to specific K-ras or p53 mutations
in this study.
Few studies have focused on subjects with a family history of
pancreatic cancer. A case report described the characteristics of a
mucinous pancreatic duct hyperplasia with a strong family history
of pancreatic carcinoma.43 This reported patient had K-ras muta-
tions, with 5 of the 7 duct lesions harboring activating point muta-
tions in codon 12 of K-ras. Four were Gfi A transitions, and a fifth
was a G fi C transversion. In contrast, these lesions did not harbor
any mutations in exons 5–8 of the p53 gene, nor was there overex-
pression of the p53 protein as determined by immunohistochemistry.
TABLE V – LOGISTIC REGRESSION MODEL TO PREDICT p53 EXON 6
MUTATIONS IN PANCREATIC ADENOCARCINOMAS FROM EGYPT
AND THE UNITED STATES








United States 12.92 (0.82–204.94) 0.068
Sex
Female 1
Male 3.19 (0.28–36.71) 0.352
Smoking
No 1







United States 24.24 (1.49–393.38) 0.025
Sex
Female 1
Male 3.43 (0.31–38.33) 0.317
Farming-related occupation
No 1




United States 8.72 (0.77–99.12) 0.081
Sex
Female 1
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This finding indicated that K-ras mutation is an early event.43 All
the subjects in our study had Stage II or III disease and exhibited
the same results: 3 of 4 had K-ras mutations, but only 1 was
detected with p53 mutations, which also suggests that K-ras muta-
tions occur earlier than p53 mutations. Another study reported a
possible relationship of family history of cancer to the expression
of p53 in pancreatic tumors.44 A lower incidence of p53 expres-
sion observed in patients with a family history of cancer suggests
normal expression of p53 protein is present in a majority of
patients who develop pancreatic tumors related to other inherited
or familial risk factors.44
Our study has strengths that support the validity of the findings.
First, the histopathological diagnosis and confirmation of pancre-
atic cancer diagnoses by a single pathologist is an advantage. Sec-
ond, the comparability of age, gender and tumor stage through our
case matching method minimized the bias of comparison between
tumors included in the study. Third, the heavily polluted locale
from which patients were recruited in Egypt was an ideal place to
examine the role of intense environmental exposures on pancreatic
carcinogenesis. However, the lack of information about the ethnic-
ity of US patients limited our ability to make inferences about the
relationship between mutational types and ethnicity among US
patients. For example, African-Americans have higher risk for
pancreatic cancer than whites.45 Another limitation of our study was
the eliciting of family history of cancer for US patients from the
medical records with its possible recall bias and misclassification.
There might have been some incomplete comparability between
the 2 sources of lifestyle factors’ information. However, medical
records at M. D. Anderson are comprehensive and several ongoing
projects aim at eliciting detailed lifestyle and behavioral factors.
It is interesting to note that the results of this study did not show
lower K-ras mutation rates in tumors from Egyptian patients com-
pared with tumors from US patients, as shown in our previous study
comparing colorectal cancers from the 2 countries (11% in tumors
from Egypt vs. 67% in tumors from the US).3 However, the types of
mutations were significantly different in the pancreatic tumors from
the 2 countries. The K-ras gene may play a different role in the mo-
lecular pathway in different cancers. K-rasmutation is an early event
in pancreatic cancer,46 and the majority of pancreatic cancer tumors
should have K-ras mutations, but the time at which the mutation
occurs may be induced by different environmental exposures.40,47–50
In summary, pancreatic cancers from Egyptian patients in this
study had a unique pattern of K-ras and p53 mutations that was
significantly different from the patterns of mutations detected in
tumors from US patients. The differences in K-ras and p53 muta-
tions may be associated with specific environmental exposures,
such as organochlorine pesticides or heavy metals, especially in
the heavily polluted region where the Egyptian patients were
recruited.24 Future studies should compare the variety of muta-
tions for patients in different regions in Egypt and the US with dif-
ferent pollution levels. Such studies may provide more evidence
to support the association between mutational types and environ-
mental exposures. Determining the level of cadmium and other
heavy metals in blood or tissue of pancreatic cancer patients, and
examining their association with mutational types, may provide
clues about the etiology of pancreatic cancer and the role of gene–
environmental interactions in pancreatic carcinogenesis.
Acknowledgement
We appreciate the technical assistance of P. Scott Houlihan.
References
1. Soliman AS, Bondy ML, Levin B, Hamza MR, Ismail K, Ismail S,
Hammam HM, el-Hattab OH, Kamal SM, Soliman AG, Dorgham
LA, McPherson RS et al. Colorectal cancer in Egyptian patients under
40 years of age. Int J Cancer 1997;71:26–30.
2. Soliman AS, Bondy ML, Raouf AA, Makram MA, Johnston DA,
Levin B. Cancer mortality in Menofeia, Egypt: comparison with U.S.
mortality rates. Cancer Causes Control 1999;10:349–54.
3. Soliman AS, Bondy ML, El-Badawy SA, Mokhtar N, Eissa S,
Bayoumy S, Seifeldin IA, Houlihan PS, Lukish JR, Watanabe T, Chan
AO, Zhu D et al. Contrasting molecular pathology of colorectal carci-
noma in Egyptian and Western patients. Br J Cancer 2001;85:1037–46.
4. Soliman AS, El-Ghawalby N, Ezzat F, Bondy ML, Soultan A, Abdel-
Wahab M, Fathy O, Ebidi G, Bassiouni N, El-Ghawalbi A, Levin B,
Abbruzzese JL. Unusually high rate of young-onset pancreatic cancer
in the east Nile delta region of Egypt. Int J Gastrointest Cancer
2002;32:143–51.
5. Siegel FR, Slaboda ML, Stanley DJ. Metal pollution loading, Manzala
Lagoon, Nile delta, Egypt: implications for aquaculture. Environ Geol
1994;23:89–98.
6. Stanley DJ, McRea JE, Jr, Waldron JC. Nile delta drill core and sam-
ple database for 1985–1994: Mediterranean basin (MEDIBA) pro-
gram, Report No. 37. Washington, DC: Smithsonian Institution, 1996.
7. Stanley DJ, Warne AG. Nile delta in its destruction phase. J Coast
Res 1998;14:794–825.
8. Dekov VM, Komy Z, Araujo F, Van Put A, Van Grieken R. Chemical
composition of sediments, suspended matter, river water and ground
water of the Nile (Aswan-Sohag traverse). Sci Total Environ 1997;
201:195–210.
9. Reinhardt EG, Stanley DJ, Schwarcz HP. Human-induced desaliniza-
tion of Manzala lagoon, Nile delta, Egypt: evidence from isotopic
analysis of benthic invertebrates. J Coast Res 2001;17:431–42.
10. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A,
Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;
55:10–30.
11. Fryzek JP, Garabrant DH, Greenson JK, Schottenfeld D. A review of
the epidemiology and pathology of pancreas cancer. Int J Gastrointest
Cancer 1997;2:99–100.
12. Blot WJ, Fraumeni JF, Stone BJ. Geographic correlates of pancreas
cancer in the United States. Cancer 1978;42:373–80.
13. Ibrahim AS, Hussein H, Ismail K, Hablas A, Bar I, Ramadan M.
Cancer profile in Gharbiah-Egypt. Middle East Cancer Consortium,
2002.
14. Yamasawa K, Nio Y, Dong M, Yamaguchi K, Itakura M. Clinicopa-
thological significance of abnormalities in Gadd45 expression and its
relationship to p53 in human pancreatic cancer. Clin Cancer Res 2002;
8:2563–9.
15. American Joint Committee on Cancer. Exocrine pancreas. In: American
joint committee on cancer: AJCC cancer staging manual, 5th edn.
Philadelphia, PA: Lippincott, 1997. 121–6.
16. Porta M. Commentary. In: Von Hoff DD, Evans DB, Hruban RH, eds.
Pancreatic cancer, 1st edn. Massachusetts: Jones & Bartlett, 2005,
113–17.
17. Begg CB, Zhang ZF. Statistical analysis of molecular epidemiology
studies employing case-series. Cancer Epidemiol Biomarkers Prev
1994;3:173–5.
18. Schroeder JC, Weinberg CR. Use of missing-data methods to correct
bias and improve precision in case-control studies in which cases are
subtyped but subtype information is incomplete. Am J Epidemiol
2001;154:954–62.
19. Hartge P, Chatterjee N, Wacholder S, Brody LC, Tucker MA, Struew-
ing JP. Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers:
effects of reproductive history. Epidemiology 2002;13:255–61.
20. Alguacil J, Porta M, Kauppinen T, Malats N, Kogevinas M, Carrato A.
PANKRAS II Study Group. Occupational exposure to dyes, metals,
polycyclic aromatic hydrocarbons and other agents and K-ras activation
in human exocrine pancreatic cancer. Int J Cancer 2003;107:635–41.
21. Chan AO, Soliman AS, Zhang Q, Rashid A, Bedeir A, Houlihan PS,
Mokhtar N, Al-Masri N, Ozbek U, Yaghan R, Kandilci A, Omar S
et al. Differing DNA methylation patterns and gene mutation frequen-
cies in colorectal carcinomas from Middle Eastern countries. Clin
Cancer Res 2005;11:8281–7.
22. Soliman AS, Wang X, DiGiovanni J, Eissa S, Morad M, Vulimiri S,
Mahgoub KG, Johnston DA, Do KA, Seifeldin IA, Boffetta P, Bondy
ML. Serum organochlorine levels and history of lactation in Egypt.
Environ Res 2003;92:110–7.
23. Soliman AS, Vulimiri SV, Kleiner HE, Shen J, Eissa S, Morad M,
Taha H, Lukmanji F, Li D, Johnston DA, Lo HH, Lau S et al. High
levels of oxidative DNA damage in lymphocyte DNA of premeno-
pausal breast cancer patients from Egypt. Int J Environ Health Res
2004;14:121–34.
24. Kriegel AM, Soliman AS, Zhang Q, El-Ghawalby N, Ezzat F, Soultan A,
Abdel-Wahab M, Fathy O, Ebidi G, Bassiouni N, Hamilton SR,
Abbruzzese JL et al. Serum cadmium levels in pancreatic cancer patients
from the east Nile delta region of Egypt. Environ Health Perspect 2006;
114:113–19.
25. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW,
Vogelstein B, Hamilton SR. Allelic loss of chromosome 18q and prog-
nosis of colorectal cancer. N Engl J Med 1994;331:213–21.
1460 SOLIMAN ET AL.
26. Fujiwara T, Stolker JM, Watanabe T, Rashid A, Longo P, Eshleman JR,
Booker S, Lynch HT, Jass JR, Green JS, Kim H, Jen J et al. Accumulated
clonal genetic alterations in familial and sporadic colorectal carcinoma
with widespread instability in microsatellite sequence. Am J Pathol 1998;
153:1063–78.
27. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR,
Vogelstein B, Kinzler KW. Molecular determinants of dysplasia in
colorectal lesions. Cancer Res 1994;54:5523–6.
28. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA,
Schwab G, Janssen JW, Bartram CR. High frequency of Ki-ras codon
12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:
1037–41.
29. Scarpa A, Capelli P, Villaneuva A, Zamboni G, Lluis F, Accolla R,
Mariuzzi G, Capella G. Pancreatic cancer in Europe: Ki-ras gene
mutation pattern shows geographical differences. Int J Cancer 1994;57:
167–71.
30. Nagata Y, Abe M, Motoshima K, Nakayama E, Shiku H. Frequent gly-
cine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human
pancreatic cancer in Japanese. Jpn J Cancer Res 1990;81:135–40.
31. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA,
Kloppel G. Ki-ras oncogene activation in preinvasive pancreatic can-
cer. Gastroenterology 1992;102:230–6.
32. Weyrer K, Feichtinger H, Haun M, Weiss G, Ofner D, Weger AR,
Umlauft F, Grunewald K. p53, Ki-ras, and DNA ploidy in human pan-
creatic ductal adenocarcinomas. Lab Invest 1996;74:279–89.
33. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH,
Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos
JL. K-ras oncogene activation in adenocarcinoma of the human pan-
creas. A study of 82 carcinomas using a combination of mutant-
enriched polymerase chain reaction analysis and allele-specific oligo-
nucleotide hybridization. Am J Pathol 1993;143:545–54.
34. Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J.
Frequency of K-ras mutations in pancreatic intraductal neoplasias
associated with pancreatic ductal adenocarcinoma and chronic pancre-
atitis: a meta-analysis. Neoplasia 2005;7:17–23.
35. Pernick NL, Sarkar FH, Philip PA, Arlauskas P, Shields AF, Vaitkevicius
VK, Dugan MC, Adsay NV. Clinicopathologic analysis of pancreatic
adenocarcinoma in African Americans and Caucasians. Pancreas 2003;
26:28–32.
36. Yamaguchi K, Chijiiwa K, Torato N, Kinoshita M, Tanaka M. Ki-ras
codon 12 point and P53 mutations: a molecular examination of the
main tumor, liver, portal vein, peripheral arterial blood and para-aortic
lymph node in pancreatic cancer. Am J Gastroenterol 2000;95:1939–45.
37. Song MM, Nio Y, Dong M, Tamura K, Furuse K, Tian YL, He SG,
Shen K. Comparison of K-ras point mutations at codon 12 and p21
expression in pancreatic cancer between Japanese and Chinese
patients. J Surg Oncol 2000;75:176–85.
38. van der Heijden MS, Kern SE. Molecular genetic alterations in cancer-
associated genes. In: Von Hoff DD, Evans DB, Hruban RH, eds. Pan-
creatic cancer, 1st edn. Massachusetts: Jones & Bartlett, 2005.31–41.
39. Howe JR, Conlon KC. The molecular genetics of pancreatic cancer.
Surg Oncol 1997;6:1–18.
40. Porta M, Malats N, Jariod M, Grimalt JO, Rifa J, Carrato A, Guarner
L, Salas A, Santiago-Silva M, Corominas JM, Andreu M, Real FX.
Serum concentrations of organochlorine compounds and K-ras muta-
tions in exocrine pancreatic cancer. Lancet 1999;354:2125–9.
41. Rall CJ, Yan YX, Graeme-Cook F, Beauchamp R, Yandell DW,
Povoski SP, Rustgi AK. Ki-ras and p53 mutations in pancreatic ductal
adenocarcinoma. Pancreas 1996;12:10–7.
42. Blanck HM, Tolbert PE, Hoppin JA. Patterns of genetic alterations in pan-
creatic cancer: a pooled analysis. Environ Mol Mutagen 1999;33:111–22.
43. DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg
FM, Allison DC, Cameron JL, Offerhaus GJ. Overexpression of p53
protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;
101:684–8.
44. Dergham ST, Dugan MC, Arlauskas P, Du W, Vaitkevicius VK,
Crissman JD, Sarkar FH. Relationship of family cancer history to the
expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in
pancreatic adenocarcinoma. Int J Pancreatol 1997;211:225–34.
45. Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic can-
cer: an overview. Cancer Detect Prev 2003;27:87–93.
46. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for
pancreatic cancer. Clin Cancer Res 2000;6:2969–72.
47. Weiderpass E, Partanen T, Kaaks R, Vainio H, Porta M, Kauppinen T,
Ojajarvi A, Boffetta P, Malats N. Occurrence, trends and environment
etiology of pancreatic cancer. Scand J Work Environ Health 1998;24:
165–74.
48. Ojajarvi IA, Partanen TJ, Ahlbom A, Boffetta P, Hakulinen T, Jourenkova
N, Kauppinen TP, Kogevinas M, Porta M, Vainio HU, Weiderpass E,
Wesseling CH. Occupational exposures and pancreatic cancer: a meta-
analysis. Occup Environ Med 2000;57:316–24.
49. Porta M, Ayude D, Alguacil J, Jariod M. Exploring environmental
causes of altered ras effects: fragmentation plus integration? Mol Car-
cinog 2003;36:45–52.
50. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet
2004;363:1049–57.
1461MOLECULAR PATHOLOGIC FEATURES OF PANCREATIC CANCER IN EGYPTIAN AND US PATIENTS
